The LATAM women hypoactive sexual desire disorder treatment market accounted for $131 million in 2019, and is expected to reach $170 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.
Hypoactive sexual desire disorder (HSDD) is the most common type of sexual dysfunction that occurs in adult women globally, manifested by lack of sex interest for a period of six months or more, owing to personal distress or fluctuating sex hormones during menstrual cycle. Hypoactive sexual desire disorder is also known as female sexual interest/arousal disorder. HSDD is currently on the rise in adult women population, which causes low self-confidence and less connection with partners.
Hypoactive sexual desire disorder is classified into primary, secondary, acquired and generalized, or situational. Accurate diagnosis of symptoms of HSDD is very critical to finalize the treatment procedure, which is either psychotherapy or pharmacotherapy. Pharmacotherapy comprises buspirone and bupropion off label non hormonal treatment for HSDD in women suffering from low libido associated with anxiety and depression. Moreover, cognitive behavior therapy is suggested to patients showing a positive response to counseling sessions with a sex therapist.
In addition, Flibanserin is currently the only drug approved by the US FDA (Food & Drug Administration) for treating HSDD in premenopausal women, owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.
The LATAM women hypoactive sexual desire disorder (HSDD) treatment market is expected to register substantial growth in the future, owing to rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue and rise in use of medicines, which induces the state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, a The rise in the number of surgical procedures, which leads to sexual dysfunction, are expected to boost the growth of LATAM women hypoactive sexual desire disorder treatment market during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Presence of strong pipeline products which present in late phases of clinical trials are expected to get approved for commercialization in the coming years. Hence, the presence of pipeline drugs offers a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.
The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone and bupropion. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, the LATAM women hypoactive sexual desire disorder treatment market size is studied across Brazil, Argentina, Chile, Colombia, Ecuador, Peru, and rest of the LATAM.
The key players operating in the LATAM women hypoactive sexual desire disorder treatment market include Aurobindo Pharma, Bristol-Myers Squibb Company, Glaxo Smith Kline (GSK), Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceuticals, Novartis (Sandoz), Sun Pharmaceutical Industries Ltd., and Cadila Healthcare (Zydus). Product launch and acquisition were the most common strategies adopted by the key players, which has led to expansion of their product offerings.
Key Benefits for Stakeholders
Key Market Segments
By Treatment Type
By Sales Channel
By Country
List of key players profiled in the report:
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Hypoactive sexual desire disorder is classified into primary, secondary, acquired and generalized, or situational. Accurate diagnosis of symptoms of HSDD is very critical to finalize the treatment procedure, which is either psychotherapy or pharmacotherapy. Pharmacotherapy comprises buspirone and bupropion off label non hormonal treatment for HSDD in women suffering from low libido associated with anxiety and depression. Moreover, cognitive behavior therapy is suggested to patients showing a positive response to counseling sessions with a sex therapist.
In addition, Flibanserin is currently the only drug approved by the US FDA (Food & Drug Administration) for treating HSDD in premenopausal women, owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.
The LATAM women hypoactive sexual desire disorder (HSDD) treatment market is expected to register substantial growth in the future, owing to rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue and rise in use of medicines, which induces the state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, a The rise in the number of surgical procedures, which leads to sexual dysfunction, are expected to boost the growth of LATAM women hypoactive sexual desire disorder treatment market during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Presence of strong pipeline products which present in late phases of clinical trials are expected to get approved for commercialization in the coming years. Hence, the presence of pipeline drugs offers a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.
The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone and bupropion. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, the LATAM women hypoactive sexual desire disorder treatment market size is studied across Brazil, Argentina, Chile, Colombia, Ecuador, Peru, and rest of the LATAM.
The key players operating in the LATAM women hypoactive sexual desire disorder treatment market include Aurobindo Pharma, Bristol-Myers Squibb Company, Glaxo Smith Kline (GSK), Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceuticals, Novartis (Sandoz), Sun Pharmaceutical Industries Ltd., and Cadila Healthcare (Zydus). Product launch and acquisition were the most common strategies adopted by the key players, which has led to expansion of their product offerings.
Key Benefits for Stakeholders
- This report entails a detailed quantitative analysis along with the current global LATAM women hypoactive sexual desire disorder treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the Key market Players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Treatment Type
- Buspirone
- Bupropion
By Sales Channel
- Hospitals
- Clinics
- Online Retailers
By Country
- Brazil
- Argentina
- Chile
- Colombia
- Ecuador
- Peru
- Rest of LATAM
List of key players profiled in the report:
- Aurobindo Pharma
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Mylan N.V.
- Novartis AG
- Palatin Technologies, Inc.
- Sprout Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadila
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Amneal Pharmaceuticals
- Allergan plc
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE
CHAPTER 5: LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL
CHAPTER 6: LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY COUNTRY
CHAPTER 7: COMPANY PROFILES
List of Tables
List of Figures
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
